Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
128.8 USD | +1.08% | +11.37% | +33.54% |
Kurzporträt
Mitarbeiterzahl: 1 314
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities
100,0
%
| 933 | 100,0 % | 1 243 | 100,0 % | +33.26% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 933 | 100,0 % | 1 243 | 100,0 % | +33.26% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 26.06.17 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 01.01.15 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 48 | 01.06.18 | |
Will Tilton
HRO | Human Resources Officer | - | - |
Alison Nasisi
HRO | Human Resources Officer | - | - |
Dallan Murray
PRN | Corporate Officer/Principal | - | 01.01.13 |
Diane Berry
PRN | Corporate Officer/Principal | - | 01.12.11 |
Ryan Brown
LAW | General Counsel | 46 | 01.01.18 |
Joseph Bratica
AUD | Comptroller/Controller/Auditor | 60 | 01.03.17 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 26.06.17 |
M. Wilsey
CHM | Chairman | 71 | 31.03.09 |
Richard Barry
BRD | Director/Board Member | 65 | 02.06.15 |
Director/Board Member | 86 | 01.06.10 | |
Stephen Mayo
BRD | Director/Board Member | 62 | 16.11.21 |
Claude Nicaise
BRD | Director/Board Member | 71 | 02.06.15 |
Michael Chambers
BRD | Director/Board Member | - | 02.06.22 |
Kathryn Boor
BRD | Director/Board Member | 65 | 02.06.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 94 505 608 | 89 365 703 ( 94,56 %) | 0 | 94,56 % |
Unternehmenskontakt
Sarepta Therapeutics, Inc.
215 First Street Suite 415
02142, Cambridge
+617 274 4000
http://www.sareptatherapeutics.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+33.54% | 12.04 Mrd. | |
-2.31% | 103 Mrd. | |
+0.56% | 95.71 Mrd. | |
+1.69% | 22.02 Mrd. | |
-17.37% | 20.9 Mrd. | |
-9.30% | 17.85 Mrd. | |
-41.01% | 16.21 Mrd. | |
-14.85% | 15.52 Mrd. | |
+3.21% | 13.86 Mrd. | |
-24.71% | 8.08 Mrd. |
- Börse
- Aktien
- A1J1BH Aktie
- Unternehmen Sarepta Therapeutics, Inc.